Skip to main content
AXNinactive

AOXING PHARMACEUTICAL COMPANY, INC.

·Commercial·CEO: Zhenjiang Yue
OncologyPain

AXN evidence brief

What we can confirm

BioSniper Score:
6.7 / 10
Lead Asset:
tilidine (Approved)

What it means

The company data is ready for cross-source review; unsupported conclusions remain unknown.

What to watch

BioSniper Score: 6.7 / 10 · Lead Asset: tilidine (Approved)
BioSniper AIPage evidence connected

Prepared research question

What matters most for AXN—catalysts, financial risk and supporting evidence?

Run cited research

Traceable citations · Unknowns marked

6.7/10

BioSniper Score

Based on 2 of 6 signals

Limited data coverage

Market Cap

—

Cash Runway

—

Lead Asset

tilidine (Approved)

Next Catalyst

—

Tracking 1 pipeline candidate for AOXING PHARMACEUTICAL COMPANY, INC..

Run AOXING PHARMACEUTICAL COMPANY, INC. through your own thesis

Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.

Your protocol can:

  • Turn available AOXING PHARMACEUTICAL COMPANY, INC. facts into screen rules or deeper checks
  • Show cited findings, blockers, and unresolved evidence together
  • Save the logic and rerun it as the company evidence changes
Run a thesis on this company — freeRun a thesis on this company

Score breakdownBased on 2 of 6 signals · derived from public data

Cash RunwayN/A

Cash runway data unavailable

Financial HealthN/A

Financial health data unavailable

Pipeline Maturity10.0

Lead: Approved

Pipeline Breadth3.3

1 candidate

Catalyst MomentumN/A

No upcoming catalysts tracked

Insider SignalN/A

No insider transactions in the last 180 days

Pipeline

Run my thesis on this company

Governance

Run my thesis on this company

Frequently asked questions

What is AOXING PHARMACEUTICAL COMPANY, INC.'s lead drug candidate?

AOXING PHARMACEUTICAL COMPANY, INC.'s most advanced tracked candidate is tilidine (Approved) for acute, moderate to severe pain, and chronic cancer-related pain.

Who is the CEO of AOXING PHARMACEUTICAL COMPANY, INC.?

Zhenjiang Yue is the chief executive officer of AOXING PHARMACEUTICAL COMPANY, INC. (AXN).

What therapeutic areas does AOXING PHARMACEUTICAL COMPANY, INC. focus on?

AOXING PHARMACEUTICAL COMPANY, INC. develops therapies across Oncology, Pain.

923 companies304,846 SEC filings22,651 clinical trials100% citation-verification pass rate (7d)How we verify →

The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.